Limited Effects of Class II Transactivator-Based Immunotherapy in Murine and Human Glioblastoma.
A Katherine TanAurelie HenryNicolas GoffartSofie van LogtestijnVincent BoursElly M HolPierre A J T RobePublished in: Cancers (2023)
these results question the therapeutic potential of CIITA-mediated immunotherapy in glioblastoma.